Document is current

Any future updates will be listed below

Utility of baseline, interim and end-of-treatment 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase

Crossref DOI link: https://doi.org/10.1038/srep41057

Published Online: 2017-01-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark